Founded in 1987, Seelos Therapeutics, Inc. (NASDAQ:SEEL) is headquartered in New York, New York, USA, with 11 full-time employees. It is a clinical-stage biopharmaceutical company that focuses on the development and treatment of central nervous system, respiratory diseases and other diseases Technology and treatment methods.
Seelos Therapeutics, Inc. (SEEL):
Seelos Therapeutics is focused on achieving the most effective product development to address the major unmet needs of central nervous system diseases and rare diseases.
The main projects of Seelos Therapeutics are:
- SLS-002, an intranasal racemic ketamine, is used to treat suicidal behavior caused by post-traumatic stress disorder and depression.
- SLS-006, a single-agent dopamine agonist for patients with early Parkinson’s disease.
On February 19, 2019, Seelos Therapeutics announced a final agreement with Bioblast Pharma Ltd., in which Seelos obtained all the development and commercial rights of Bioblast’s proprietary Trehalose (Trehalose) 90 mg/mL IV. Trehalose is currently a research molecule that has been studied in pre-phase II clinical studies of more than 70 patients with two rare diseases, and has proven favorable safety and efficacy signals.